Mimic of MDS boards likes to test
copper deficiency
Diseases associated with psuedo-pelger huet cells
CML, AML, MDS
Good risk cytogenetic findings in MDS
*-Y
- del5q
- del11q
- del12p
- del20q
Poor risk cytogenetic findings in MDS
How to think of risk stratification of mutations in MDS
Treatment of choice for MDS w/ 5q-
lenalidomide
hypoplastic MDS managment
treated similar to aplastic anemia with triple IST
contraindication to use of iron chelators
CrCL<40
MDS bone marrow findings
Demographics - gender + ethnicity at higher risk
Men at higher risk
White people at higher risk
*think MDS patient
Other MDS RF’s
hypoplastic MDS management
immunosuppression (treated similarly to aplastic anemia)
- cyclosporine + ATG
Mutation with most favorable prognosis in MDS
SF3B1
Disease associated with SRSF2
CMML